Skip to main content
PLOS One logoLink to PLOS One
. 2020 Jan 29;15(1):e0227874. doi: 10.1371/journal.pone.0227874

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

Irene A Kretchy 1, Vincent Boima 2,*, Kofi Agyabeng 3, Augustina Koduah 1, Bernard Appiah 4
Editor: Tim Mathes5
PMCID: PMC6988959  PMID: 31995606

Abstract

Medication adherence is a key health outcome that reflects the health and general well-being of patients with hypertension. Challenges with adherence are common and associated with clinical, behavioural and psychosocial factors. This study sought to provide data on the extent of medication adherence among male patients with hypertension and their biopsychosocial predictors. Patient and clinical characteristics, psychological distress, insomnia and sexual dysfunction were hypothesized to predict outcomes of medication adherence. Utilizing quantitative data from a hospital-based cross-sectional study from 358 male out-patients with hypertension attending a tertiary hospital in Ghana, medication adherence was associated with age, marital status, educational level, income, duration of diagnosis, number of medications taken and sexual dysfunction. These findings support the need for biopsychosocial interventions aiming at promoting adherence while taking these factors into consideration for the benefit of improving the health and general well-being of male patients with hypertension.

Introduction

Hypertension is an important but treatable public health problem globally. It is estimated to have increased from 442 million in 1990 to 874 million in 2015 [1]. Hypertension is a significant risk factor for cardiovascular disease and stroke: the two leading causes of adult mortality worldwide [1]. Hypertension is also an important public health problem in sub-Saharan Africa. There has been an increase in the prevalence of hypertension in sub-Saharan Africa, and rates in some semi-urban and urban communities are comparable with the prevalence in the United States of America [2, 3]. Prevalence of hypertension in Ghana ranges from 19.2–32.8% in rural areas to 25.5–48% in urban areas [2, 4]. Similarly, studies in Nigeria showed that prevalence of hypertension in rural areas range from 21 to 25% while in semi-urban and urban areas prevalence ranged from 27 to 46% [5, 6].

Blood pressure control is generally poor among persons with hypertension in sub-Saharan Africa, and efforts to improve blood pressure control are needed [7] There are challenges in the management of hypertension in sub-Saharan Africa in part due to the low rates of hypertension awareness, treatment and control [3]. In Ghana, the reported prevalence of awareness, treatment and control of hypertension were up to 54%, 31% and 13% respectively [2, 4]. For Nigeria, the prevalence of hypertension awareness and treatment were up to 29.4 and 11.3%, while blood pressure control was achieved in 3% of patients with hypertension in community-based studies [3, 6, 8].

The poor blood pressure control among persons with hypertension in sub-Saharan Africa is related to the complex interplay of factors such as lack of knowledge about hypertension, beliefs that are discordant with those of the traditional medical paradigm regarding the causes and treatment of hypertension [9]. Thus, patients’ beliefs may be discordant with good practices that help to control high blood pressure [4, 9]. Additionally, patients may not adhere to antihypertensive medications which is the extent to which their medication taking behaviour is consistent with recommendations by their health practitioners because of factors such as the inability to afford the medications [10], co-morbidities including insomnia [11, 12], psychological distress [13] and side effects of the anti-hypertensive medications including sexual dysfunction in men [1416].

Hypertension and antihypertensive therapy have long been associated with sexual dysfunction (specifically erectile dysfunction) [17]. In 2010, Amidu et al, explored the prevalence of sexual dysfunction among Ghanaian men presenting with various medical conditions and found that the general prevalence of sexual dysfunction was 59.8% of which 50% of this rate was found among men with hypertension [18]. A previous study in South Africa [19] including reviews of studies [20, 21] and guidelines for hypertension management [22] have shown strong associations among sexual dysfunction, hypertension and antihypertensive therapy. Sexual dysfunction is accompanied by psychological problems, emotional stress, somatic complains and social isolation [23, 24]. The relative risk of sexual dysfunction among hypertensive patients is two times higher compared with normotensive patients [25]. Sexual dysfunction among hypertensive patients significantly impact on the quality of life of the patients and their partners [17, 25]. Thus, patients may not adhere to their medications as shown in previous studies [14, 16, 26], resulting in increased risk of morbidity and mortality as a result of complications of hypertension.

To the best of our knowledge, no studies in Ghana have reported sexual dysfunction, psychological distress, and medication adherence of persons with hypertension and their associations to each other given that sexual dysfunction with mixed presentations of mood and behavioural disturbances such as impaired sleep are common in male patients with hypertension and impaired sleep also contributes to the development of psychiatric disorders [2729], it is necessary to explore this topic in Ghana.

Thus, this study aimed to assess the association among sexual dysfunction, psychological distress, sleep disturbances, and medication adherence in a group of male patients with hypertension in Accra, Ghana.

Methods

Study design

This was a single centre, hospital-based cross-sectional study conducted at the Korle Bu Teaching Hospital in the Greater Accra Region of Ghana. Data were collected between January 2017 and April 2017.

Setting and participants

Three hundred and fifty-eight participants were recruited at the specialist, medical and general outpatient clinics of the hospital. The hospital has 2000-bed capacity with 17 clinical and diagnostic departments. It has an average monthly attendance of 716 patients and an average admission rate of 250 patients per day.

Eligibility criteria for this study included male patients age 18 years and older; diagnosis of hypertension, use of antihypertensive medication for the past 12 months and ability to provide informed consent to participate in the study. Hypertension was defined as Systolic Blood Pressure (SBP) ≥ 140mmHg and Diastolic Blood Pressure (DBP) ≥ 90mmHg or patients who were on treatment for hypertension. Study questionnaire and other validated data capturing instruments were same for all the specialist units and the general medical outpatient clinics. Participants who satisfied the inclusion criteria were recruited into the study according to the order in which they reported to the out-patient department starting from the first patient. Three research assistants were trained for three days for the interviewer-assisted data collection process. The research assistants read the questions to the respondents, and completed the questionnaires based on the respondents’ answers. A minimum required sample size of 351 was obtained using the formula:

n0=(Deff)(Z2)2p(1p)e2

Where

n0 = minimum required sample size,

Z2 = standard normal value of 95% confidence level = 1.96

e = level of precision/margin of error = 0.05

p = prevalence of adherence among patients with hypertension in Ghana and Nigeria = 33.3% [30]

Deff = design effect = 1.03.

Assuming a 10% non-response rate, the sample size was computed to be 386.

Variables

The main study outcome variable was medication adherence. Demographic and other variables such as age, educational background, marital status, average monthly income, presence of comorbidities, number and type of prescribed medications and length of time since diagnosis of disease were assessed. Psycho-behavioural measures of sexual dysfunction, psychological distress, and sleep problems were also recorded.

Sexual dysfunction

The 15-item International Index for Erectile Function (IIEF) was used to assess sexual dysfunction in the following domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction dysfunction [31]. The Erectile Function domain consisted of six questions, Organismic function and Sexual desire–two questions each, Intercourse Satisfaction–three questions, with the Overall Satisfaction having two question. Each of the 15 questions was measured on a scale of 0–5. The questions were measured on a scale of 0–5 with each domain score generated by computing total score for the items in each domain. The scores were negatively scaled implying that lower scores indicated high dysfunction and vice versa [31]. The scale’s reliability coefficient in this study based on the Cronbach alpha was 0.959. (Table 1).

Table 1. The total scores were then categorized into five ordered groups as follows.

Erectile function Orgasmic function Sexual desire Intercourse Satisfaction Overall satisfaction
Interpretation (Code used) Cut-off Score Cut-off Score Cut-off Score Cut-off Score Cut-off Score
Severe dysfunction (5) 0–6 0–2 0–2 0–3 0–2
Moderate dysfunction (4) 7–12 3–4 3–4 4–6 3–4
Mild to moderate dysfunction (3) 13–18 5–6 5–6 7–9 5–6
Mild dysfunction (2) 19–24 7–8 7–8 10–12 7–8
No dysfunction (1) 25–30 9–10 9–10 13–15 9–10

Psychological distress

The 10-item Kessler Psychological Distress Scale measured distress based on the experience of symptoms of anxiety and depression in the most recent 4-week period. The responses to each question was rated from 1 (none of the time) to 5 (all of the time). The total scores ranged from 10 to 50 with scores less than 20, 20–24, 25–29 and 30 and above indicating no, mild, moderate and severe mental disorder respectively [32]. This scale was reliable having a Cronbach alpha value of 0.886.

Insomnia

Insomnia was measured using the Athens Insomnia scale which assesses eight factors [33]. The first five factors are related to nocturnal sleep and the last three factors identify daytime dysfunction. These factors are rated on a 0–3 scale. The individual’s sleep was evaluated from the cumulative score of all factors and reported as their sleep outcome. A cut-off score ≥6 was used to indicate insomnia [33, 34]. The scale’s reliability coefficient had a Cronbach alpha of 0.834.

Medication adherence

The rate of adherence to medications was measured using the Medication Adherence Questionnaire (MAQ) which is quick to administer and score [35]. Each item elicited a ‘yes’ or ‘no’ response about patterns of past medication use. High (0), medium (1–2) and low adherence (3–4) were obtained when a patient answered ‘no’ to all the questions, ‘yes’ to one question, and ‘yes’ to two or more questions respectively. The MAQ has shown good validity and reliability in previous studies on cardiovascular disease populations and has also shown good correlation coefficients with other objective measures of adherence and clinical outcomes [35, 36]. In this study the reliability coefficient based on the Cronbach alpha was 0.701.

Ethics

The study protocol was approved by the Institutional Review Board at the Noguchi Memorial Research Institute for Medical Research, University of Ghana, Legon (035-16/17). A written informed consent was sought from each participant before inclusion in the study.

Statistical analysis

Data were analyzed using STATA (version 14.1). Descriptive statistics for continuous variables were presented in terms of means and standard deviations for normally distributed data while medians and interquartile ranges were reported for data not normally distributed. Categorical variables were reported in terms of frequencies and percentages. Skewness, kurtosis, and Shapiro-Wilk tests were used to assess the normality of continuous variables. Chi-square test of independence was used to test for association between the categorical independent variables and medication adherence level. One-way ANOVA test was used to compare the average age across patients’ medication adherence levels while the Kruskal Wallis test was used to compare the medians when the data was not normally distributed. Ordered logistic regression models were used to determine associated factors of the level of medication adherence. The likelihood ratio chi-square, Wolfe Gould and Wald tests were used to test for the parallel/proportional odds assumption. The model had level of medication adherence (Low-1, medium-2, and high-3) as the outcome variable with background characteristics, sexual dysfunctions, psychological distress, and insomnia as explanatory variables. All statistical tests were done at 5% significance level. Multiple imputation by chained equation was used to impute for missing information using the predictive mean matching imputation method. Table A shows the questionnaire item response rates (Table A in S1 File).

Results

Sociodemographic data

An estimated 2400 patients visited the OPD during the study period and were potentially eligible for the study. Of the1680 patients who were not new cases, 672 were male patients and 386 were approached based on the eligibility criteria. Of the 386 male patients who were eligible and were approached for the study, 358 agreed to participate in the study, representing a 92.7% response rate (Figure A in S1 File). The other 28 participants declined participation on account of fatigue as some of them travel overnight from distant parts of the country to KBTH for review.

The participants had an average age of 56.2±13.50 years (range: 25–91years). The participants were mostly married (70.7%), earned between GH₡ 500 to GH₡ 999 (about US$117 to US$.234) monthly and had either secondary (33.2%) or tertiary (47.8%) education. More than half of the study participants had lived with hypertension for at least five years (52.5%). The participants had a daily average sleep of 7 hours with each person taking a median number of 2 medicines per their medication regiment (Table 2).

Table 2. Background characteristics of male patients with hypertension receiving treatment at the KBTH.

  Frequency Percentage
Age: Mean ± SD 358 56.20 ± 13.50
Marital Status
Single 28 7.82
Married 253 70.67
Divorced 56 15.64
Widowed 21 5.87
Educational level
None 19 5.31
Basic 49 13.69
Secondary 119 33.24
Tertiary 171 47.77
Income
Below 500 75 20.95
500–999 155 43.30
1000–2999 103 28.77
≥ 3000 25 6.98
Length of Diagnosis
< 2 Years 72 20.11
2–4 Years 98 27.37
5–7 Years 88 24.58
8–10 Years 36 10.06
> 10 Years 64 17.88
Number Of Medications: Median (LQ,UQ) 358 2(2,4)
On non- anti-hypertensive medication
No 298 83.24
Yes 60 16.76
Non- anti-hypertensive medication
Antidiabetic 21 5.87
Statins 23 6.42
Antiplatelet 26 7.26
Anticoagulant 7 1.96
Sleeping Hours: Median (LQ,UQ) 358 7(6,8)

SD: Standard deviation, LQ: Lower quartile, UQ: Upper quartile

Clinical characteristics of participants

Table 3 presents the levels of sexual dysfunction and other clinical disorders among the study participants. All the study participants (100%) experienced some levels of orgasmic and sexual desire dysfunctions. Dysfunctions between mild and severe levels were also recorded for erectile dysfunction (91.3%), intercourse satisfaction dysfunction (90.2%) and overall satisfaction dysfunction (99.4%).

Table 3. Distribution of clinical disorders among male patients with hypertension receiving treatment at the KBTH.

  Frequency Percentage
Erectal function
Mean ± SD 12.49 ± 8.56
No dysfunction 31 8.66
Mild dysfunction 58 16.20
Mild to medium dysfunction 111 31.01
Medium dysfunction 68 18.99
Severe dysfunction 90 25.14
Orgasmic function
Mean ± SD 3.47 ± 2.30
Mild dysfunction 25 6.98
Mild to medium dysfunction 114 31.84
Medium dysfunction 116 32.40
Severe dysfunction 103 28.77
Sexual desire
Mean ± SD 4.39 ± 2.11
Mild dysfunction 43 12.01
Mild to medium dysfunction 151 42.18
Medium dysfunction 108 30.17
Severe dysfunction 56 15.64
Intercourse Satisfaction
Mean ± SD 6.34 ± 4.39
No dysfunction 35 9.78
Mild dysfunction 51 14.25
Mild to medium dysfunction 90 25.14
Medium dysfunction 80 22.35
Severe dysfunction 102 28.49
Overall satisfaction
Mean ± SD 3.75 ± 1.93
No dysfunction 2 0.56
Mild dysfunction 22 6.15
Mild to medium dysfunction 116 32.40
Medium dysfunction 117 32.68
Severe dysfunction 101 28.21
Psychological distress
Mean ± SD 21.60 ± 7.75
No mental disorder 156 43.58
Mild mental disorder 78 21.79
Medium mental disorder 72 20.11
Severe mental disorder 52 14.53
Insomnia
Mean ± SD 7.64 ± 4.40
No 130 36.31
Yes 228 63.69
Medication adherence Level
Mean ± SD 2.07 ± 1.43
Low 151 42.18
Medium 143 39.94
High 64 17.88

SD: Standard deviation

Insomnia and Psychological distress were prevalent at 63.7% (228/358) and 56.4% (202/358) respectively (Table 3)). The average Psychological distress score was 21.6(range:10–50) and that of medication adherence was 2.1(range:0–4). The categorization of medication adherence scores was low (42.8%), moderate (39.9%) and high (17.9%) (Table 2).

Factors associated with medication adherence

The bivariate analysis of factors associated with level of medication adherence (Table 4) showed significant associations with age, marital status, educational level, income level, length of diagnosis and number of medications taken (p<0.05). The One-way ANOVA test showed high medication adherence levels among the younger study participants compared with the older ones (low-59.3 ± 13.3 vs medium-55.1 ± 13.2 vs high-51.6 ± 13.0, p<0.001). In addition, all clinical factors except sexual desire dysfunction were significantly associated with the level of medication adherence among the study participants (p<0.05).

Table 4. Association between background characteristics, clinical disorders and medication adherence level among male patients with hypertension receiving treatment at the KBTH.

  Medication Adherence level  
  Low Medium High p-value
Age: Mean ± SD 59.25 ± 13.34 55.06 ± 13.16 51.56 ± 12.97 <0.001
Marital Status 0.001
Single 11(39.29) 9(32.14) 8(28.57)
Married 121(47.83) 90(35.57) 42(16.6)
Divorced 12(21.43) 36(64.29) 8(14.29)
Widowed 7(33.33) 8(38.10) 6(28.57)
Educational Level 0.035
None 12(63.16) 5(26.32) 2(10.53)
Basic 29(59.18) 17(34.69) 3(6.12)
Secondary 46(38.66) 48(40.34) 25(21.01)
Tertiary 64(37.43) 73(42.69) 34(19.88)
Income 0.004
Below 500 35(46.67) 26(34.67) 14(18.67)
500–999 55(35.48) 65(41.94) 35(22.58)
1000–2999 42(40.78) 48(46.6) 13(12.62)
3000–4999 19(76.00) 4(16.00) 2(8.00)
Length of Diagnosis <0.001
< 2 Years 27(37.5) 33(45.83) 12(16.67)
2 To 4 Years 34(34.69) 42(42.86) 22(22.45)
5 To 7 Years 27(30.68) 43(48.86) 18(20.45)
8 To 10 Years 16(44.44) 13(36.11) 7(19.44)
> 10 Years 47(73.44) 12(18.75) 5(7.81)
Number Of Medications: Median (LQ,UQ) 3(2,4) 2(1,3) 2(2,3) <0.001
Sleeping Hours: Median (LQ,UQ) 7(6,8) 7(6,8) 6(5,8) 0.293
Clinical Disorders
Insomnia <0.001
No 74(56.92) 37(28.46) 19(14.62)
Yes 77(33.77) 106(46.49) 45(19.74)
Erectile Function <0.001
No Dysfunction 20(64.52) 8(25.81) 3(9.68)
Mild Dysfunction 24(41.38) 23(39.66) 11(18.97)
Mild to Medium Dysfunction 35(31.53) 46(41.44) 30(27.03)
Medium Dysfunction 13(19.12) 40(58.82) 15(22.06)
Severe Dysfunction 59(65.56) 26(28.89) 5(5.56)
Orgasimic Function <0.001
Mild Dysfunction 11(44) 9(36) 5(20)
Mild to Medium Dysfunction 49(42.98) 44(38.6) 21(18.42)
Medium Dysfunction 29(25) 59(50.86) 28(24.14)
Severe Dysfunction 62(60.19) 31(30.1) 10(9.71)
  Sexual Desire 0.338
Mild Dysfunction 19(44.19) 18(41.86) 6(13.95)
Mild to Medium Dysfunction 59(39.07) 56(37.09) 36(23.84)
Medium Dysfunction 46(42.59) 47(43.52) 15(13.89)
Severe Dysfunction 27(48.21) 22(39.29) 7(12.5)
Intercourse Satisfaction <0.001
No Dysfunction 20(57.14) 11(31.43) 4(11.43)
Mild Dysfunction 25(49.02) 21(41.18) 5(9.8)
Mild to Medium Dysfunction 20(22.22) 43(47.78) 27(30)
Medium Dysfunction 29(36.25) 34(42.5) 17(21.25)
Severe Dysfunction 57(55.88) 34(33.33) 11(10.78)
Overall Satisfaction 0.013
No Dysfunction 1(50) 0(0) 1(50)
Mild Dysfunction 7(31.82) 8(36.36) 7(31.82)
Mild to Medium Dysfunction 46(39.66) 44(37.93) 26(22.41)
Medium Dysfunction 41(35.04) 54(46.15) 22(18.8)
Severe Dysfunction 56(55.45) 37(36.63) 8(7.92)
Psychological Distress <0.001
No Mental Disorder 91(58.33) 43(27.56) 22(14.1)
Mild Mental Disorder 25(32.05) 38(48.72) 15(19.23)
Medium Mental Disorder 15(20.83) 42(58.33) 15(20.83)
Severe Mental Disorder 20(38.46) 20(38.46) 12(23.08)  

SD: Standard deviation, LQ: Lower quartile, UQ: Upper quartile.

Testing the parallel or proportional odds assumption using the likelihood ratio chi-square (χ2 = 4.63, p = 0.705), Wolfe Gould (χ2 = 39.79,p = 0.390) and the Wald (χ2 = 40.96,p = 0.342) test confirmed that it was satisfied. From the unadjusted ordered logistic regression models, all the factors were significantly related to the level of medication adherence (p<0.05) except for sexual desire and number of sleeping hours, as shown in Table 4 (S1A). However, the adjusted multiple ordered logistic regression model showed that, age, income level, number of medications, marital status and the number of years the study participants had been diagnosed of hypertension were significantly associated with medication adherence.

The odds of a patient adhering to medication decreases by 3% with every year advancement in age (AOR: 0.97, 95%CI: 0.95–0.99). Study participants who were married had 21% lesser odds of having better medication adherence than study participants who were single.

Participants who had been diagnosed for over ten years had 67% less odds of having better adherence compared with those who have been diagnosed for less than two years (Table 5)

Table 5. Effects of background factors and clinical disorders on level of medication adherence among male patients with hypertension receiving treatment at the KBTH.

  Unadjusted Adjusted
  UOR 95% CI p-value AOR 95% CI p-value
Age 0.97 0.96–0.98 < 0.001 0.97 0.95–0.99 0.002
Income 0.004 0.044
Below 500 ref ref
500–999 1.51 0.89–2.55 0.82 0.43–1.56
1000–2999 1.06 0.6–1.85 0.51 0.25–1.01
≥ 3000 0.27 0.1–0.74 0.24 0.07–0.80
Sleeping Hours 0.98 0.89–1.09 0.704 0.94 0.83–1.07 0.339
Educational level 0.006 0.186
None ref ref
Basic 1.08 0.37–3.16 0.45 0.13–1.62
Secondary 2.71 1.02–7.25 0.87 0.28–2.72
Tertiary 2.74 1.05–7.19 1.10 0.36–3.39
Number of Medications 0.76 0.67–0.87 <0.001 0.84 0.71–0.99 0.035
Marital Status 0.035 0.017
Single ref ref
Married 0.59 0.28–1.27 0.79 0.32–1.94
Divorced 1.14 0.49–2.67 1.24 0.44–3.48
Widowed 1.18 0.4–3.48 4.06 1.07–15.42
Length of Diagnosis <0.001 0.011
< 2 Years ref ref
2–4 Years 1.23 0.70–2.16 1.15 0.6–2.19
5–7 Years 1.31 0.73–2.32 1.57 0.8–3.09
8–10 Years 0.87 0.41–1.85 1.00 0.41–2.43
> 10 Years 0.24 0.12–0.48 0.33 0.13–0.80
Insomnia <0.001 0.691
No ref ref
Yes 2.25 1.47–3.42 1.12 0.63–2
Erectile Function <0.001 0.108
No Dysfunction ref ref
Mild Dysfunction 2.64 1.09–6.37 2.41 0.75–7.75
Mild to Medium Dysfunction 4.25 1.88–9.63 2.72 0.73–10.11
Medium Dysfunction 5.14 2.18–12.08 2.29 0.56–9.46
Severe Dysfunction 0.9 0.39–2.1 0.64 0.11–3.68
Orgasimic Function <0.001 0.220
Mild Dysfunction ref ref
Mild to Medium Dysfunction 1 0.44–2.28 0.87 0.32–2.38
Medium Dysfunction 1.85 0.81–4.22 1.65 0.56–4.84
Severe Dysfunction 0.48 0.21–1.12 1.55 0.41–5.95
  Sexual Desire 0.295 0.967
Mild Dysfunction ref ref
Mild to Medium Dysfunction 1.42 0.75–2.68 1.19 0.53–2.65
Medium Dysfunction 1.05 0.54–2.02 1.08 0.42–2.78
Severe Dysfunction 0.86 0.41–1.82 1.2 0.41–3.49
Intercourse Satisfaction <0.001 0.382
No Dysfunction ref ref
Mild Dysfunction 1.27 0.55–2.94 0.99 0.32–3.11
Mild to Medium Dysfunction 4.21 1.95–9.08 2.05 0.63–6.63
Medium Dysfunction 2.35 1.08–5.12 1.65 0.49–5.57
Severe Dysfunction 1.03 0.48–2.21 2.51 0.64–9.79
Overall Satisfaction 0.006 0.163
No Dysfunction ref ref
Mild Dysfunction 1 0.04–24.3 0.15 0–4.9
Mild to Medium Dysfunction 0.64 0.03–14.34 0.06 0–1.9
Medium Dysfunction 0.67 0.03–15.05 0.05 0–1.57
Severe Dysfunction 0.3 0.01–6.68 0.04 0–1.52
Psychological Distress <0.001 0.212
No Mental Disorder ref ref
Mild Mental Disorder 2.49 1.48–4.19 1.88 1–3.54
Medium Mental Disorder 3.41 2.01–5.78 1.75 0.9–3.4
Severe Mental Disorder 2.28 1.24–4.19   1.46 0.71–3.01  

UOR: Unadjusted odd ratio, AOR: Adjusted odds ratio, CI: Confidence interval, ref: reference category

Discussions

Poor adherence to prescribed medications has been reported among patients with hypertension with a number of factors being implicated to play various roles in this health outcomes [26, 37, 38]. To the best of our knowledge, no study has reported the associations among patient characteristics, psycho-behavioural factors and medication adherence in male patients with hypertension in Ghana.

The study observed that medication adherence was affected by age, marital status, educational level, income, duration of diagnosis, number of medications taken and sexual dysfunction.

Socio-demographic factors have been reported to contribute to the medication adherence behaviour of patients with hypertension in general and among hypertensive men in particular [13, 14, 39, 40]. Contrary to other studies where increasing age was associated with improved medication adherence, this study showed that the odds of patients adhering to medication significantly decreased by 3% with every year advancement in age. Previous studies have examined the effect of age on medication adherence with varied results. Some studies have reported high levels of medication adherence with increased age [39, 41] while others have shown otherwise or reported no association between age and medication adherence [11, 42]. For this study participants, as they get older, adhering to their medications become difficult probably due to the increase in the number of medicines taken, increase with years of living with the disease and the experience with sexual dysfunction and other complications either related to the hypertensive disease or as a result of the side effects of the antihypertensive medications. Sexual dysfunction is usually encountered in hypertensive men with hypertension disease and erectile dysfunction increases with age [14]. Similarly, the desire to avoid any challenges with sexual dysfunction may have compelled the married participants to poorly adhere to their medicines compared with their unmarried counterparts.

The findings from this study extend to previous studies on medication adherence where sexual intercourse was perceived as a high priority and patients with hypertension engage in strategies such as discontinuing their antihypertensive medications or selectively adhering to their medications so that they can have sexual intercourse [16, 25]

Lastly, our study revealed that sociodemographic characteristics; income and education were positively associated with medication adherence suggesting that respectively, educated men and men of affluence probably better understood the importance of taking their medication or had better access to their medications with no financial barriers to medications leading to better adherence [40]. Again, this group of participants could communicate their problems with the clinicians for early evaluation and intervention which could help to enhance adherence [36].

Implications for healthcare

Because hypertension is a chronic condition and patients will have to live with it for the rest of their lives, it will be necessary for clinicians to pay attention to older patients and those who have lived with the disease for some time. Although it may be quite a sensitive issue to bring up in patient-healthcare practitioner interactions, clinicians can take the initiative to ask about the sexual health of their patients because having a good sexual function is important for men [43]. Biopsychosocial interventions [44] having pharmacological, psychological and social facets can then be implemented for such patients so that their level of adherence to their prescribed medications will not be compromised for improved quality of life outcomes.

Implications for policy

As patients live with hypertension in the long term, they are exposed to the long-term effects of the disease and also medications used for treating hypertension. Thus, health practitioners must effectively and efficiently educate their patients regarding hypertension, its treatment and also the implications of non-adherence to their medications. Policy makers should implement measures to make health education on long-term diseases such as hypertension an integral part of medical practice which should be practiced regularly. Also, potential barriers to medication adherence should be included in the national Standard Treatment Guidelines to prompt practitioners to educate patients and advocate for complete adherence to medicines prescribed.

Communication-related interventions including use of the mass media, social media and mobile phones could help reach more adults with effective messages about a need for adhering to antihypertensive medications. Such interventions should also include the benefits of adhering to treatments.

Strengths of the study

To the best of our knowledge, this is the first study in Ghana to assess medication adherence in male patients with hypertension in order to understand the extent of the challenge for appropriate interventions to be recommended. Again, with a general paucity of information on the psycho-behavioural perspective of medication adherence, the approach we used is a strength of our study.

Limitations

Our study had some limitations. Although hypertension affects both males and females, this study concentrated only on males to assess male predominant factors associated with the high medication non-adherence rate among male hypertensive patients compared with their female counterparts as reported in previous studies [30]. Also, the perspective of the partners of these male patients were missing. However, with the current evidence from our study, there is a great opportunity for studies involving female patients with hypertension. The use of a cross-sectional design limits the ability to determine the directions of the associations found in this study. Another limitation of this study was the use of self-reported measures for adherence and insomnia instead of objective tools which could affect the right estimation of these levels. In addition, these self-reported measures may be prone to recall bias. To reduce the potential of recall bias, we limited the timeline during which these behaviours occurred to the most recent 4-week period. We also note that, this was a study conducted in a teaching hospital in Ghana so the findings cannot be generalised to all male patients with hypertension in Ghana.

Conclusion

This study found that the medication adherence behaviour of male patients with hypertension was significantly associated with age, marital status, educational level, income, duration of diagnosis, number of medications taken and sexual dysfunction. Biopsychosocial interventions aiming at promoting adherence while taking these pharmacological, psychological and social factors into consideration may be beneficial for improving the health and general well-being of male patients with hypertension.

Supporting information

S1 File. Supporting Information.

Figure A Table A

(DOCX)

Acknowledgments

The authors will like to acknowledge the staff and patients at the specialist, medical and general outpatient clinics at the Korle-Bu Teaching Hospital.

Data Availability

All relevant data are in the Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Huffman MD, Lloyd-Jones DM. Global Burden of Raised Blood Pressure: Coming Into Focus. Jama. 2017;317(2):142–3. 10.1001/jama.2016.19685 [DOI] [PubMed] [Google Scholar]
  • 2.Agyemang C, Bruijnzeels MA, Owusu-Dabo E. Factors associated with hypertension awareness, treatment, and control in Ghana, West Africa. Journal of human hypertension. 2006;20(1):67 10.1038/sj.jhh.1001923 [DOI] [PubMed] [Google Scholar]
  • 3.Hendriks ME, Wit FW, Roos MT, Brewster LM, Akande TM, De Beer IH, et al. Hypertension in sub-Saharan Africa: cross-sectional surveys in four rural and urban communities. PloS one. 2012;7(3):e32638 10.1371/journal.pone.0032638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bosu WK. Epidemic of hypertension in Ghana: a systematic review. BMC public health. 2010;10(1):418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Oghagbon E, Okesina A, Biliaminu S. Prevalence Of Hypertension And Associated Variables In PaidWorkers In Ilorin, Nigeria. Nigerian Journal of Clinical Practice. 2008;11(4). [PubMed] [Google Scholar]
  • 6.Ulasi II, Ijoma CK, Onwubere BJ, Arodiwe E, Onodugo O, Okafor C. High prevalence and low awareness of hypertension in a market population in Enugu, Nigeria. International journal of hypertension. 2011;2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Seedat YJ. Why is control of hypertension in sub-Saharan Africa poor? Cardiovascular journal of Africa. 2015;26(4):193 10.5830/CVJA-2015-065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Awobusuyi J, Kukoyi O, Ibrahim M, Atiba M. Indices of kidney damage and cardiovascular disease risk factors in a semiurban community of Iloye, South-west Nigeria. International journal of nephrology. 2011;2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Spencer J, Phillips E, Ogedegbe G. Knowledge, attitudes, beliefs, and blood pressure control in a community-based sample in Ghana. Ethnicity and Disease. 2005;15(4):748 [PubMed] [Google Scholar]
  • 10.Gellad WF, Grenard JL, Marcum ZAJTAjogp. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. 2011;9(1):11–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ambaw AD, Alemie GA, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC public health. 2012;12(1):282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhan Y, Chen R, Zhang F, Wang J, Sun Y, Ding R, et al. Insomnia and its association with hypertension in a community-based population in China: a cross-sectional study. 2014;6(1):88–93. 10.1136/heartasia-2013-010440 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kretchy IA, Owusu-Daaku FT, Danquah S. Locus of control and anti-hypertensive medication adherence in Ghana. Pan African medical journal. 2014;17 Suppl 1:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ferrini MG, Gonzalez-Cadavid NF, Rajfer J. Aging related erectile dysfunction—potential mechanism to halt or delay its onset. Translational andrology and urology. 2017;6(1):20 10.21037/tau.2016.11.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kretchy IA, Owusu-Daaku FT, Danquah SA, Asampong E. A psychosocial perspective of medication side effects, experiences, coping approaches and implications for adherence in hypertension management. Journal of clinical hypertension. 2015;21(1):19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Voils CI, Sandelowski M, Dahm P, Blouin R, Bosworth HB, Oddone EZ, et al. Selective adherence to antihypertensive medications as a patient-driven means to preserving sexual potency. Patient preference and adherence. 2008;2:201 10.2147/ppa.s3796 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? The Journal of Clinical Hypertension. 2006;8(4):269–74. 10.1111/j.1524-6175.2006.04708.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Amidu N, Owiredu WK, Woode E, Appiah R, Quaye L, Gyasi-Sarpong CK, et al. Sexual dysfunction among Ghanaian men presenting with various medical conditions. Reproductive biology and endocrinology. 2010;8(1):118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ker JA. Hypertension and sexual dysfunction. South African family practice. 2012;54(2). [Google Scholar]
  • 20.Doumas M, Boutari C, Viigimaa MJ. Arterial hypertension and erectile dysfunction: an under-recognized duo. The journal of clinical hypertension. 2016;14(4):1–7. [Google Scholar]
  • 21.Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. European heart journal. 2013;34(27):2034–46. 10.1093/eurheartj/eht112 [DOI] [PubMed] [Google Scholar]
  • 22.Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH. Antihypertensive drugs and male sexual dysfunction: a review of adult hypertension guideline recommendations. Journal of cardiovascular pharmacology and therapeutics. 2016;21(3):233–44. 10.1177/1074248415598321 [DOI] [PubMed] [Google Scholar]
  • 23.Bocchio M, Pelliccione F, Mihalca R, Ciociola F, Necozione S, Rossi A, et al. Treatment of erectile dysfunction reduces psychological distress. International journal of andrology. 2009;32(1):74–80. 10.1111/j.1365-2605.2007.00820.x [DOI] [PubMed] [Google Scholar]
  • 24.Bohdana B, Vrublová Y. The effect of antihypertensive therapy on human sexuality. Central European journal of nursing and midwifery. 2014; 6(2): 237–244. [Google Scholar]
  • 25.Viigimaa M, Vlachopoulos C, Lazaridis A, Doumas M. Management of erectile dysfunction in hypertension: Tips and tricks. World journal of cardiology. 2014;6(9):908 10.4330/wjc.v6.i9.908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017; 96(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Glozier N, Martiniuk A, Patton G, Ivers R, Li Q, Hickie I, et al. Short sleep duration in prevalent and persistent psychological distress in young adults: the DRIVE study. Sleep. 2010;33(9):1139–45. 10.1093/sleep/33.9.1139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sivertsen B, Harvey AG, Lundervold AJ, Hysing M. Sleep problems and depression in adolescence: results from a large population-based study of Norwegian adolescents aged 16–18 years. European child & adolescent psychiatry. 2014;23(8):681–9. [DOI] [PubMed] [Google Scholar]
  • 29.Sutton ELJMC. Psychiatric disorders and sleep issues. 2014;98(5):1123–43. [DOI] [PubMed] [Google Scholar]
  • 30.Boima V, Ademola AD, Odusola AO, et al. Factors Associated with Medication Nonadherence among Hypertensives in Ghana and Nigeria. International Journal of Hypertension. 2015; Article ID 205716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30. 10.1016/s0090-4295(97)00238-0 [DOI] [PubMed] [Google Scholar]
  • 32.Andrews G, Slade T. Interpreting scores on the Kessler psychological distress scale (K10). Australian and New Zealand journal of public health. 2001;25(6):494–7. 10.1111/j.1467-842x.2001.tb00310.x [DOI] [PubMed] [Google Scholar]
  • 33.Soldatos CR, Dikeos DG, Paparrigopoulos T. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. Journal of psychosomatic researc. 2000;48(6):555–60. [DOI] [PubMed] [Google Scholar]
  • 34.Uchmanowicz I, Markiewicz K, Uchmanowicz B, Kołtuniuk A, Rosińczuk J. The relationship between sleep disturbances and quality of life in elderly patients with hypertension. Clinical interventions in aging. 2019;14:155 10.2147/CIA.S188499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. Journal of the American Pharmacists Association. 2011; 1;51(1):90–4. 10.1331/JAPhA.2011.09154 [DOI] [PubMed] [Google Scholar]
  • 36.Nguyen T-M-U,La Caze A, Cottrell N.Validated adherence scales used in a measurement-guided medication management approach to target and tailor a medication adherence intervention: a randomised controlled trial. BMJ Open 2016; 6:e013375 10.1136/bmjopen-2016-013375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bhagavathula A, Abegaz T, Gebreyohannes E, Shehab A. Non-Adherence to Antihypertensive Drugs: A Systematic Review and Meta-Analysis. Value in Health. 2016;19(7):A657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.de Terline DM, Kane A, Kramoh KE, Toure IA, Mipinda JB, Diop IB, Nhavoto C, Balde DM, Ferreira B, Houenassi MD, Ikama MS. Factors associated with poor adherence to medication among hypertensive patients in twelve low and middle income Sub-Saharan countries. PloS one. 2019. July 10;14(7):e0219266 10.1371/journal.pone.0219266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Holt EW, Muntner P, Joyce CJ, Webber L, Krousel-Wood MA. Health-related quality of life and antihypertensive medication adherence among older adults. Age and ageing. 2010;39(4):481–7. 10.1093/ageing/afq040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bochkareva EV, Butina EK, Kim IV, Kontsevaya AV, Drapkina OM, Leon D, McKee M. Adherence to antihypertensive medication in Russia: a scoping review of studies on levels, determinants and intervention strategies published between 2000 and 2017. Archives of Public Health. 2019;77(1):43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Morris AB, Li J, Kroenke K, Bruner‐England TE, Young JM, Murray MD. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy: The Journal of human pharmacology and drug therapy. 2006;26(4):483–92. [DOI] [PubMed] [Google Scholar]
  • 42.Braverman J, Dedier J. Predictors of medication adherence for African American patients diagnosed with hypertension. Ethnicity & disease. 2009;19(4):396. [PubMed] [Google Scholar]
  • 43.Gerbild H, Larsen CM, Graugaard C, Josefsson KA. Physical activity to improve erectile function: A systematic review of intervention studies. Sexual medicine. 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wilhelmsen NC, Eriksson T. Medication adherence interventions and outcomes: an overview of systematic reviews. European Journal of Hospital Pharmacy. 2019;26(4):187–92. 10.1136/ejhpharm-2018-001725 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Tim Mathes

31 Oct 2019

PONE-D-19-23246

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

PLOS ONE

Dear Dr. Boima ,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by 30. November 2019. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tim Mathes

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

3. Please state in your methods section the participant recruitment date.

4. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type of informed consent you obtained (for instance, written or verbal). If consent was verbal, please specify how you recorded/documented participant consent and whether your ethics committee approved this consent procedure.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Additional Editor Comments:

This is an interesting manuscript. However, the reviewers and I have some major concerns that should be revised regarding the methods before I it can be published.

In addition to the comments of the reviewer please consider the following issues.

Methods

- Please report the results according the STROBE guideline as far as possible

- Please provide all information on the assumptions of the sample size calculation

- Please provide a definition for adherence

- Please specify how adherence was categorized for the logistic regression analysis

- Please specify how continuous predictors were categorized for the logistic regression

- Please clarify why you perform two univariate analysis that answer the same question (table 3 and table 4). Was one of the analyses planned as sensitivity analysis? In particular, the Chi-square analysis in table 3 and univariate analysis of categorical variables in table 4 is redundant, which might be confusing for the reader.

Results

- Please describe the patient-flow in detail (e.g. using a flow-chart). In addition, information on missing data for the outcome as well as predictors should be provided.

- You does not perform a confirmatory study with an a-priory defined hypothesis, Therefore, please delete all signs (*) to indicate statistical significance below the tables

- The value of the Chi-square statistic can be deleted

- If written in English, please provide the study protocol as supplemental material.

- Please indicate if the study was registered in any trials registry

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you very much for giving an opportunity to review the present manuscript. The authors have evaluated the psycho-behavioural factors associated with medication adherence among male patients with hypertension in Ghana. They found that medication adherence of male hypertensive patients was significantly associated with age, marital status, educational level, income, duration of diagnosis, number of medication taken, and sexual dysfunction. This study is quite interesting in point that it evaluates medication adherence from the perspective of behavioural and psychosocial, as well as clinical factors. I think however that there are some improvements that should be made before publication. And the number of pages and lines should be described in the manuscript, because it is hard to point out.

[Methods]

Participants (or limitation section)

1. As it is stated in the “limitations”, more detailed reason is necessary why this study population was only male patients.

Measures

2-1. Is the “type of prescribed medication” only antihypertensive agent? And, type of medication (e.g. antidiabetic agent) is not seen in Table 1. If you investigate the type of prescribed medication other than antihypertensive agent, it should be added in the results section and Table 1.

2-2. Did you analyse the “patients comorbidity” as clinical characteristics? I think that comorbidity is one of the most important factors that affect medication adherence in patients with chronic diseases.

[Results]

Background and clinical characteristics

3-1. An average age of 56.2±SD?

3-2. Erectile dysfunction (92.3%)? It is 91.3% in Table 2.

[Discussions]

4-1. Socio-demographic factors have been reported to contribute to the medication adherence behaviour of patients with hypertension…

References are required in this sentence.

4-2. Similar to other studies where increasing age was associated with improved medication adherence, this study showed that the odds of patients adhering to medication significantly decreased by 3% with every year advancement in age.

I think “Similar to” is incorrect. The results of this study showed that increasing age was associated with “poor” medication adherence.

4-3. For this study participants, as they get older, adhering to their medications become difficult probably due to the increase in the number of medicines taken, increase with years of living with the disease and the experience with sexual dysfunction and other complications either related to the hypertensive disease or as a result of the side effects of the antihypertensive medications…

You should analyse the relationship between age (e.g. younger (<65) vs older (>65)) and the number of medicines taken, the length of diagnosis, sexual dysfunction and other complications, and discuss about those comparing with previous reports.

4-4. Lastly, among the sociodemographic characteristics, income and education were associated with medication adherence...

It is unclear which part is derived from the data of this study or that of previous reports. You should re-organize this part.

4-5. Implications for healthcare

You should explain “biopsychosocial interventions” in detail to the readers to understand using previous reports.

4-6. Implications for healthcare

Although it may be quite a sensitive issue to bring up “during” patient-healthcare practitioner interactions...

during?

4-7. Implications for policy

practised → practiced?

Reviewer #2: In this study, authors set out to investigate medication adherence among male patients with hypertension, as well as factors associated with adherence with a focus on psycho-social determinants including sexual dysfunction and sleep difficulties. A number of factors were identified, and authors suggest the potential contribution of these psycho-social factors in medication (non)adherence. The paper is generally well written. I have few comments/questions for your consideration.

1) How did you arrive at this sample size? There is limited information on the sampling strategy. Simply stating participants were randomly recruited seems insufficient. How was the sampling randomization done? In addition, how many potentially eligible participants were approached/invited prior to obtaining final study sample? Response rate?

2) A number of measurement tools/questionnaires were used to assess sexual dysfunction, insomnia and medication adherence. Have they been previously validated in similar Ghanaian populations? Otherwise, it might be good to comment on how you assured validity of these tools in your study.

3)Almost half of your study population had tertiary education. This seems quite high. Is this representative of the Ghanaian population? Was there some form of selection bias author may want to comment on?

4) At the beginning of your results section, you mention the average age, and after you write 'SD'. Can you please provide the actual standard deviation.

5) This study is from a single-centre and hospital based. In the limitations, please, provide further discussion on the external validity of your study findings.

Secondly, you want to consider discussing further the limitations of self-reported tools (and compared to objective measures) as used to assess adherence, insomnia, etc.

Thank you.

Reviewer #3: 1. Although authors try to mention under limitations section why conducted only on male, still need further clarification

2. Why authors not used the standard tool for assessing adherence, e.g MMAS-8? Need to mention and describe it.

3. Analysis section has problems, e.g Multivariate analyses should include the percentage/frequency's of each variable with respec to adherent vs non adherent. Require extensive revision in this part.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Motoyasu Miyazaki

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Tim Mathes

6 Dec 2019

PONE-D-19-23246R1

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

PLOS ONE

Dear Dr. Boima

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

A requirement for acceptance is that the results are reported according the STROBE statement for cross-sectional studies: https://www.strobe-statement.org/index.php?id=available-checklists​ 

In particular, information on patient flow/missing data and (avoiding) potential bias  should be provided. 

We would appreciate receiving your revised manuscript by 14.12.2019. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tim Mathes

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Authors of this manuscript have addressed most of my comments/concerns. I have no further major comments. Thank you.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Motoyasu Miyazaki

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Jan 29;15(1):e0227874. doi: 10.1371/journal.pone.0227874.r004

Author response to Decision Letter 1


16 Dec 2019

I am submitting a revised manuscript entitled “Psycho-behavioural factors associated with medication adherence and health-related quality of life of male out-patients with hypertension in a Ghanaian hospital” for publication in PLOS ONE journal. All comments have been addressed point-by-point as suggested by the reviewers. There are no legal restrictions on sharing a de-identified data set. The results have been reviewed according to STROBE statement for cross-sectional studies.

All authors declare no conflict of interest.

I will be grateful if this manuscript can be considered for publication in your journal.

Thank you.

Yours Sincerely

Dr. Vincent Boima

Attachment

Submitted filename: Response to Reviewers.doc

Decision Letter 2

Tim Mathes

19 Dec 2019

PONE-D-19-23246R2

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

PLOS ONE

Dear Dr. Boima ​,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

There is still no information on missing data in the statistic section (STROBE item 12c) as well as in the results section (STROBE item 13).

I cannot imagine that all patients who agreed to participate provided fully complete questionnaires (i.e. no missing answer at all). Do you include only participants with complete questionnaires (i.e. without any missing response to any variable)? This means you performed a complete case analysis. If so, please describe this in the publication.

Otherwise pleas specific how you handled missing responses (e.g. mean imputation) and in the case information on the adherence measures (outcome) in addition information on the amount of missing values.  

In addition, please provide information who performed the assessment. Were the patients interviewed or completed a patient questionnaire, or other?

Please be more cautiously in the interpretation in consideration of risk of bias (e.g. self-reported adherence measures, sensible questions) (STROBE item 20). No information is given on generalizability (STROBE item 21).

Further information can be found here: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.0040297&type=printable

We would appreciate receiving your revised manuscript by Feb 02 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tim Mathes

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Jan 29;15(1):e0227874. doi: 10.1371/journal.pone.0227874.r006

Author response to Decision Letter 2


23 Dec 2019

23rd Dec 2019

The Editor

PLOS ONE

Dear Sir/Madam,

RE: SUBMISSION OF REVISED MANUSCRIPT

I am submitting a revised manuscript entitled “Psycho-behavioural factors associated with medication adherence and health-related quality of life of male out-patients with hypertension in a Ghanaian hospital” for publication in PLOS ONE journal. All comments have been addressed point-by-point as suggested by the reviewers. There are no legal restrictions on sharing a de-identified data set. The results have been reviewed according to STROBE statement for cross-sectional studies as shown below.

Comments Response

There is still no information on missing data in the statistic section (STROBE item 12c) as well as in the results section (STROBE item 13).

Multiple imputation by chained equation was used to impute for missing information using the predictive mean matching imputation method. Appendix 1 (table 5) shows the questionnaire item response rates (page 5)

In addition, please provide information who performed the assessment. Were the patients interviewed or completed a patient questionnaire, or other Three research assistants were trained for three days for the interviewer-assisted data collection process. The research assistants read the questions to the respondents, and completed the questionnaires based on the respondents’ answers. (Page 3)

Please be more cautiously in the interpretation in consideration of risk of bias (e.g. self-reported adherence measures, sensible questions) (STROBE item 20 these self-reported measures may be prone to recall bias. To reduce the potential of recall bias, we limited the timeline during which these behaviours occurred to the most recent 4-week period. (page 8)

No information is given on generalizability (STROBE item 21).

Further information can be found here We also note that, this was a study conducted in a teaching hospital in Ghana so the findings cannot be generalised to all male patients with hypertension in Ghana.

(page 8)

Data Attached as new compressed zipped folder

All authors declare no conflict of interest.

I will be grateful if this manuscript can be considered for publication in your journal.

Thank you.

Yours Sincerely

Dr. Vincent Boima

Decision Letter 3

Tim Mathes

2 Jan 2020

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

PONE-D-19-23246R3

Dear Dr. Boima,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Tim Mathes

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Tim Mathes

13 Jan 2020

PONE-D-19-23246R3

Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital

Dear Dr. Boima:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tim Mathes

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Supporting Information.

    Figure A Table A

    (DOCX)

    Attachment

    Submitted filename: R2R.doc

    Attachment

    Submitted filename: Response to Reviewers.doc

    Data Availability Statement

    All relevant data are in the Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES